<DOC>
	<DOCNO>NCT00514904</DOCNO>
	<brief_summary>The purpose study demonstrate , 2-10 year old subject , non-inferiority meningococcal vaccine GSK134612 compare license meningococcal vaccine Mencevax™ . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Non-Inferiority Meningococcal Vaccine GSK134612 Versus Mencevax™ 2-10 Year Old Subjects</brief_title>
	<detailed_description>Multicentre study 2 treatment group . Two blood sample take , prior one month vaccination , first 75 % enrolled subject per country independent treatment group .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent guardian comply requirement protocol . A male female , include , 2 10 year age time vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Previously complete routine childhood vaccination best his/her parents'/guardians ' knowledge . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol within one month dose vaccine . Previous vaccination meningococcal polysaccharide vaccine serogroup A , C , W135 and/or Y ( subject 6 year ) within last five previous year ( subject 6 year old ) . Previous vaccination meningococcal polysaccharide conjugate vaccine serogroups A , C , W135 and/or Y . Previous vaccination tetanus toxoid within last month . History meningococcal disease . Any confirm suspected immunosuppressive immunodeficient condition ( congenital secondary ) , include human immunodeficiency virus ( HIV ) infection , base medical history physical examination.. History reaction allergic disease likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>meningococcal vaccine</keyword>
	<keyword>immunogenicity</keyword>
</DOC>